Dyne Therapeutics, Inc.
19.19USD
-1.1200 (-5.51%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Operating Income | -182 | -125 | -116 | -114 | -116 | -122 | -97 | -106 |
| Net Income | -179 | -121 | -112 | -108 | -111 | -115 | -90 | -97 |
| EPS (Diluted) | $-1.08 | $-0.73 | $-0.73 | $-0.76 | $-0.97 | $-1.05 | $-0.88 | $-0.96 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)